Context Therapeutics shares plunged 51% after CTIM-76 interim data showed a 29% response rate in platinum-resistant ovarian cancer patients, with two confirmed responses and disease control in four of seven evaluable subjects. H.C. Wainwright and JonesResearch held Buy ratings with $5 and $7 targets, calling the selloff a buying opportunity.
Context Therapeutics shares plunged 51% on Monday after releasing interim early-stage results for its experimental CTIM-76 therapy in platinum-resistant ovarian cancer. The drop marked the worst one-day decline in the company's trading history.
The update covered 21 patients with CLDN6-positive solid tumors, including 14 with platinum-resistant ovarian cancer. Among nine ovarian cancer patients receiving active doses, seven were evaluable: two achieved confirmed responses (29% response rate) and four showed disease stabilization, despite a median of seven prior therapies.
H.C. Wainwright retained its Buy rating with a $5 price target, noting CTIM-76’s competitive activity against peers even in heavily pretreated populations. JonesResearch also maintained a Buy rating and $7 target, calling the selloff a buying opportunity and expecting improved outcomes in future data.
Context Therapeutics plans two upcoming catalysts: initial data for CT-95 in advanced solid tumors expected in September 2026, and the first patient dosing in a CT-202 first-in-human study in Q3 2026.
